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ABSTRACT
Introduction: Glecaprevir/pibrentasvir is
approved for treating chronic hepatitis C virus
(HCV) genotypes (GT) 1–6. We evaluated real-
world effectiveness, safety, and patient-reported
outcomes of glecaprevir/pibrentasvir in under-
served patient populations, focusing on persons
who use drugs infected with HCV.
Methods: Data were pooled from nine coun-
tries (13 November 2017–31 January 2020).
Patients had HCV GT1–6, with or without
compensated cirrhosis, with or without prior
HCV treatment and received glecaprevir/pi-
brentasvir consistent with local label at their
physician’s discretion. Patients with prior
direct-acting antiviral exposure were excluded
from efficacy and quality-of-life analyses. The
percentage of patients achieving sustained
virologic response at post-treatment week 12
(SVR12) was assessed. Mean changes from
baseline to SVR12 visit in 36-Item Short-Form
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Health Survey mental and physical component
summary scores were reported. Safety was
assessed in patients receiving at least one dose
of glecaprevir/pibrentasvir.
Results: Of 2036 patients, 1701 (83.5%)
received 8-week glecaprevir/pibrentasvir. In
1684 patients with sufficient follow-up, SVR12
rates were 98.0% (1651/1684) overall, 98.1%
(1432/1459) in 8-week treated patients, 97.0%
(519/535) in persons who use drugs, and greater
than 95% across subgroups. Mean changes from
baseline in mental and physical component
summary scores were 3.7 and 2.4, respectively.
One glecaprevir/pibrentasvir-related serious
adverse event was reported; six glecaprevir/pi-
brentasvir-related adverse events led to
discontinuation.
Conclusions: Glecaprevir/pibrentasvir was
highly effective, well tolerated, and improved
quality of life in HCV-infected persons who use
drugs and other underserved patients.
Trial Registration: These multinational post-
marketing observational studies are registered
with ClinicalTrials.gov, number NCT03303599.
Keywords: Alcohol use disorder; Health-related
quality of life; Hepatitis C; Illicit drugs;
Psychiatric disorders
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Why carry out this study?
Simplification of the hepatitis C virus
(HCV) care cascade and the advent of
direct-acting antivirals can help to achieve
the World Health Organization’s 2030
HCV elimination targets.
Guidelines have attempted to simplify
treatment and enable non-liver specialists
to manage and treat low-risk patients with
HCV, who represent the majority of
patients. However, non-liver specialists
may have concerns over treatment safety
by using simplified, noninvasive
pretreatment assessments.
This study investigated the safety profile of
glecaprevir/pibrentasvir in patients
identified using previously described
noninvasive laboratory measures who
may be eligible for treatment by non-liver
specialists.
What was learned from the study?
Data from large clinical trials and real-
world studies included in this analysis
confirm that glecaprevir/pibrentasvir is
well tolerated across different patient
populations, with less than 0.1% of
patients experiencing a serious adverse
event related to treatment drugs, and no
significant hepatoxicity observed.
The safety profile of glecaprevir/
pibrentasvir may provide clinical
confidence to physicians and other non-
liver specialists treating HCV with the
opportunity to expand the treater pool, a
necessary step to meet HCV elimination
targets.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features




antivirals (DAA) have transformed the treat-
ment landscape for patients with hepatitis C
virus (HCV) infection [1–3]. Their introduction
has shifted the focus of HCV management from
meeting specific unmet medical needs of
patients to achieving the overarching goal of
HCV elimination. The World Health Organiza-
tion (WHO) has set targets for eliminating HCV
as a major public health threat by 2030 [4].
Rapid scale-up of DAA treatment for target
populations with high HCV prevalence, such as
prisoners and persons who use drugs (PWUD), is
crucial for achieving elimination [5–7]. Injec-
tion drug users, who are at high risk for trans-
mitting HCV, account for 70% of all new HCV
cases [8], and modeling studies have shown that
even modest increases in treatment of PWUD
can reduce HCV prevalence and incidence
[9, 10]. In Australia, high uptake of DAAs
among PWUD has reduced the prevalence of
active HCV infection from 51% in 2015 to 18%
in 2019 [5]. Expanding treatment to other his-
torically marginalized patients with HCV, such
as patients with psychiatric disorders or a his-
tory of alcohol abuse, as well as those who are
unemployed or have low to no education is also
important for removing barriers to achieve
elimination [11, 12].
The WHO recommends treating all adults
with chronic hepatitis C (CHC) with a
pangenotypic DAA [4], the advantages of which
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include simpler treatment regimens and
broader access in comparison to nonpangeno-
typic regimens [2]. Similarly, current guidelines
from the American Association for the Study of
Liver Diseases (AASLD) and the Infectious Dis-
eases Society of America (IDSA) and the Euro-
pean Association for the Study of the Liver
(EASL) recommend broad treatment of nearly
all individuals with CHC [13, 14]. Glecaprevir/
pibrentasvir is an interferon-free, ribavirin-free,
fixed-dose pangenotypic DAA combination
approved in the USA and Europe in 2017 for the
treatment of HCV genotypes (GT) 1–6, and
currently available in 66 countries [15]. In
clinical trials, glecaprevir/pibrentasvir demon-
strated an overall sustained virologic response
at post-treatment week 12 (SVR12) rate of 97.5%
with a favorable safety profile [15–17]. Recently,



















B 1 1062 (76.5)
[ 1 327 (23.5)
Missing 647






Other DAA 17 (0.8)
Missing 5




8 weeks 1701 (83.5)




16 weeks 40 (2.0)
Mode of HCV infection
Contaminated needle or IV drug
use
618 (30.9)
Blood product transfusion 250 (12.5)
Vertical transmission (mother to
child)
27 (1.3)




Occupational exposure 21 (1.0)
Unknown 877 (43.8)
Missing 33
Data are n (%) unless stated otherwise; percentages are
calculated from non-missing values
APRI aspartate aminotransferase-to-platelet ratio index,
DAA direct-acting antiviral, G/P glecaprevir/pibrentasvir,
GT genotype, HCV hepatitis C virus, IV intravenous,
RNA ribonucleic acid
a Prior treatment unknown for some patients
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the EXPEDITION-8 trial demonstrated that
8 weeks of glecaprevir/pibrentasvir is highly
effective and well-tolerated in treatment-naı̈ve
patients with compensated cirrhosis (CC) [18],
leading to the approval of 8-week glecaprevir/
pibrentasvir for treatment-naı̈ve patients with
HCV and GT1–6 and CC [15]. Real-world data
on glecaprevir/pibrentasvir are limited, partic-
ularly in high-risk populations, including
PWUD [19, 20].
In clinical practice, patient populations may
be more diverse and potentially less adherent to
treatment versus those in clinical trials [21],
which could impact the safety and effectiveness
of DAAs in these settings. Compared with the
general population, people with HCV have a
higher prevalence of comorbidity and multi-
morbidity [22], and patients with dual disor-
ders, such as substance and/or alcohol abuse
combined with psychiatric disorders, were his-
torically excluded from registrational trials. It is
therefore crucial to assess the effectiveness and
safety of pangenotypic DAAs in real-world
populations, particularly among PWUD and
patients with other single or dual disorders.
Real-world studies on glecaprevir/pibrentasvir
conducted in single-country cohorts demon-
strated high rates of SVR12 [19, 20, 23–26];
however, there may be a greater diversity of
patient subpopulations and treatment patterns
across multiple countries. Real-world data on
the impact of treatment with DAAs on patient
health-related quality of life (HRQOL) are also
limited, although their impact on HRQOL in
patients with CHC was documented in regis-
tration studies [27]. Patients with CHC were
shown to have diminished HRQOL [28, 29],
primarily related to the presence of fatigue and
other common extrahepatic manifestations
[30, 31]. Among PWUD, treatment of HCV with
DAAs may improve patient-reported outcomes,
including HRQOL [32], although limited data
have been reported to date. Real-world clinical
practice data on safety, effectiveness, and
HRQOL in these patients is important to over-
come barriers to treatment, to guide clinical
decisions, and to support the 2030 WHO target
of HCV elimination.
In this pooled analysis of ongoing, multina-
tional, post-marketing observational studies
(PMOS), we evaluated the real-world effective-
ness, safety, and HRQOL of glecaprevir/pi-
brentasvir in adult patients with CHC from
underserved populations, with an emphasis on




This was an interim analysis of data pooled
from AbbVie-sponsored PMOS across nine
countries: Austria, Belgium, France, Greece,
Israel, Italy, Poland, Portugal, and Switzerland
(13 November 2017–31 January 2020), which
began shortly after approval of glecaprevir/pi-
brentasvir. Eligible patients were followed from
treatment initiation until 12 weeks after the end
of treatment (EOT) or until premature discon-
tinuation. Each study was conducted in accor-
dance with local laws and regulations and
received the required approvals from the
responsible regulatory authorities, ethics com-
mittees, and/or competent authorities. Written
informed consent was obtained from all inclu-
ded patients, including permission to publish
personal health information while ensuring the
identity of the individual remains confidential.
The study protocol conformed to the ethical
guidelines of the 1964 Declaration of Helsinki,
and its later amendments. All authors had
access to relevant data, and participated in the
writing, review, and approval of the final
manuscript.
Study Population
The PMOS included patients aged at least
18 years with HCV GT1–6 infection who
received glecaprevir/pibrentasvir at the treating
physician’s discretion according to local label,
national or international recommendations,
and/or local clinical practice; patients who were
CHC treatment-naı̈ve or had been previously
treated with interferon, ribavirin, sofosbuvir, or
DAA; and those without cirrhosis or with CC.
The presence of cirrhosis was defined as
Infect Dis Ther
METAVIR stage 4, or Knodell stage 4, or Inter-
national Association for the Study of the Liver
(IASL) stage 4, or Scheuer stage 4; or Ishak
stage C 5; or by transient elastography: FibroS-
can (Echosens, Waltham, MA) C 12.5 kPa;
FibroTest (BioPredictive, Paris, France) C 0.75;




Effectiveness was measured as the percentage of
patients achieving SVR12, defined as HCV
ribonucleic acid (RNA) below the lower limit of
quantification (LLOQ, \50 IU/mL) at
12 ± 2 weeks (i.e., at least 70 days) after the last
dose of glecaprevir/pibrentasvir. On-treatment
virologic failure was defined as viral break-
through or failure to suppress HCV replication.
Viral breakthrough was defined as confirmed
HCV RNA C 100 IU/mL after HCV RNA\
LLOQ during the treatment period or confirmed
increase from nadir in HCV RNA (two consec-
utive HCV RNA measurements[ 1 log10 IU/mL
above nadir) at any time point during the
treatment period. Failure to suppress was
defined as patients with HCV RNA C LLOQ at
EOT with at least 6 weeks of treatment, where
the HCV RNA value must be collected on or
after 36 days of treatment (excludes patients
counted in the breakthrough summary).
Relapse was defined as confirmed HCV RNA
C LLOQ between EOT and 12 weeks after last
actual dose of study drug (up to and including
the SVR12 assessment time point) for a patient
with HCV RNA\ LLOQ at the final treatment
visit who completed treatment (defined as study
drug duration at least 52 days for 8 weeks, at
least 77 days for 12 weeks, or at least 103 days
for 16 weeks), excluding reinfection. Virologic
failure was defined as ‘‘other’’ virologic failure if
on-treatment HCV RNA measurements were
missing and therefore it was not possible to
determine if the failure was relapse or on-treat-
ment failure.
Health-Related Quality of Life
Patient reported-outcomes (PROs) included the
36-Item Short-Form Health Survey (SF-36, con-
sisting of eight domains and two aggregate
component scores (physical component sum-
mary [PCS] and mental component summary
[MCS]) (range 0–100; higher scores indicating
better HRQOL) and the Fatigue Severity Scale
Table 2 Comorbidities at baseline
Comorbidity, n (%) Safety population,
N = 2036
Recreational drug use
Any recreational drug use prior
to screeninga
697 (34.7)
B 12 months prior to screening 168 (8.4)








On stable opiate substitution therapy
Yes 219 (11.0)
No 1771 (89.0)
History of psychiatric disorder 200 (9.8)
History of alcohol useb 322 (18.5)
Unemployed or low to no
education
835 (45.0)
PWUD ? psychiatric disorder 127 (6.2)
PWUD ? alcohol use 223 (11.0)
PWUD ? unemployed or low to
no education
143 (7.0%)
Percentages calculated from non-missing values
PWUD people who use drugs
a Timing of drug use was unknown for 28 patients who
reported recreational drug use
b More than two drinks per day
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(FSS) (scored 1–7) [33, 34]. FSS includes nine
items relating to the extent of fatigue symptoms
and their impact on patient functioning [33].
The total score is the mean of the nine item
scores (range 1–7) with higher scores indicating
greater fatigue. The percentage of patients
achieving a minimally important difference
(MID) in PROs from baseline to the SVR12 visit
was reported [33, 35, 36]. MIDs were defined as
an increase of at least 2.5 in PCS or MCS scores
[36] and a decrease of at least 0.7 in FSS scores;
thresholds considered clinically relevant [33].
Safety
Safety was assessed by monitoring adverse
events (AEs) (including fatalities, and AEs caus-
ing study drug discontinuation) and abnormal
laboratory measurements reported in the safety
population. AEs were coded according to Med-
DRA 21.0 (Medical Dictionary for Regulatory
Activities, McLean, VA) system organ class and
preferred terms. An AE was considered treat-
ment-emergent if the reported event began or
worsened after initiation of glecaprevir/pi-
brentasvir through 30 days after glecaprevir/pi-
brentasvir dosing or if the date of onset was
missing.
Statistical Analysis
The safety population included all patients
meeting the inclusion criteria receiving at least
one dose of glecaprevir/pibrentasvir, including
those who were treated off label. The core
population included patients from the safety
population treated according to the current
label at the time of study in accordance with
their disease characteristics and with a known
drug start date, excluding patients who were
DAA-experienced. The core population with
sufficient follow-up (CPSFU) included patients
from the core population, excluding those who
did not have an HCV RNA evaluation after post-
treatment day 70 for reasons not related to
effectiveness or safety (lost to follow-up or
unavailable HCV RNA data). Patients included
in the CPSFU had one of the following: HCV
RNA data after post-treatment day 70 (not
included if the drug end date was unknown),
virologic failure (on-treatment virologic failure
or post-treatment relapse), discontinued the
study because of an AE, and had HCV
RNA\50 IU/mL at the last measurement.
Patient characteristics at baseline, including
comorbidities and patient-reported co-medica-
tion use (Anatomical Therapeutic Chemical
code 3), were summarized in the safety popu-
lation. Summary statistics (n, mean, median,
standard deviation [SD], minimum, maximum)
were generated for continuous variables, and
number and percentage of patients were repor-
ted for categorical variables. Patient-reported
treatment adherence was calculated as the per-
centage of tablets taken relative to the total
tablets expected to be taken. The percentage of
patients achieving SVR12 was calculated for the
CPSFU and a two-sided 95% confidence interval
(CI) of the percentage was computed on the
basis of the Wilson’s score method. Mean
change in total score from baseline to the SVR12
visit and the number and percentage of patients
with improvements greater than or equal to the
MID from baseline to any visit through to the
SVR12 visit, along with two-sided 95% CIs, were
reported for all PROs in the core population.
Effectiveness and PROs were reported in one or
more of the following disorders, dual disorders,
or triple disorder of interest: cirrhotic/non-cir-
rhotic, 8- or 12-week glecaprevir/pibrentasvir
duration, illegal drug use (PWUD), psychiatric
disorder, alcohol use, unemployment or low to
no education; PWUD and psychiatric disorders;
PWUD and alcohol use; and PWUD ? unem-
ployed ? low to no education. In this analysis,
key subgroups were defined as the following:
PWUD as any patient-reported illicit drug use;
alcohol use as consumption of more than two
alcoholic drinks/day; and psychiatric disorder as
a history of depression or bipolar disease,
depression and suicide/self-jury, and anxiety.
For treatment-naı̈ve GT1–6 patients with cir-
rhosis, these analyses regard 12 weeks of gle-
caprevir/pibrentasvir as the label-recommended
regimen because the study statistical analysis
plan predated the approval of 8 weeks of gle-
caprevir/pibrentasvir for these patients.
All statistical analyses were conducted using
the SAS software package (version 9.4; SAS




As of January 31, 2020, 2116 patients were
enrolled: 2036 in the safety population,
including 119 who were treated off label and
excluded from the core population; 1917 in the
core population; 1684 in the CPSFU (Fig. 1).
Twelve percent of patients (n = 233) were
excluded from the CPSFU, including 126
patients reported as lost to follow-up (Fig. 1).
Ninety patients in the safety population with
sufficient follow-up but treated off label were
excluded from the CPSFU (Supplementary
Table 1).
Demographics and Clinical Characteristics
In the safety population, 1782 (87.5%) were
non-cirrhotic and 1760 (86.7%) were HCV
treatment-naı̈ve (Table 1). As a result, 1701
(83.5%) patients were assigned to glecaprevir/
pibrentasvir for 8 weeks, whereas 295 (14.5%)
and 40 (2.0%) were assigned to glecaprevir/pi-
brentasvir for 12 and 16 weeks, respectively. In
2032 patients with available data, mean adher-
ence to treatment was 99.7% ± 2.6%.
Comorbidities
At baseline, 11.0% of patients (n/N = 219/1990)
were on stable opioid substitution therapy.
Approximately one-third of the population (n/
N = 697/2008; 34.7%) reported recreational
drug use, which was inclusive of injection drug
use. Among these, 168 had recent (within
12 months prior to screening) and 519 had
former (more than 12 months prior to screen-
ing) recreational drug use. Overall (n = 2036),
the five most common recreational drugs were
heroin (n = 451; 22.5%), cocaine (n = 158;
7.9%), marijuana (n = 77; 3.8%), hashish
(n = 58; 2.9%), and opioids (n = 27; 1.3%). Of
2036 patients who received at least one dose of
glecaprevir/pibrentasvir, 200 (9.8%) had psy-
chiatric disorders, 322 (18.5%) had a history of
alcohol use, and 835 (45.0%) were unemployed
or had low to no education (Table 2). Overall,
127 (6.2%) were PWUD with a psychiatric dis-
order, 223 (11.0%) were PWUD with a history of
alcohol use, and 143 (7.0%) were PWUD who
were unemployed and had low or no education
(Table 2). A minority of patients were coinfected
with human immunodeficiency virus (HIV; n/
N = 111/2036; 5.5%) or hepatitis B virus (HBV;
n/N = 25/2036; 1.2%).
Co-medications
Overall, 44.7% (n/N = 911/2036) of the overall
population received at least one co-medication.
Among 2036 patients, 312 (15.3%) received 1
co-medication, 431 (21.2%) received 2–4 co-
medications, 131 (6.4%) received 5–8 co-medi-
cations, and 37 (1.8%) received more than 8 co-
medications (Table 3). Additionally, approxi-
mately half of the PWUD population (n/
N = 352/697; 50.5%) received at least one co-
Table 3 Number and frequency of co-medications at
baseline
Co-medication (in ‡ 5%







1 312 (15.3) 121 (17.4)
2–4 431 (21.2) 174 (25.0)
5–8 131 (6.4) 47 (6.7)
[ 8 37 (1.8) 10 (1.4)
0 (none) 1125 (55.3) 345 (49.5)
Anxiolytics 135 (6.6) 89 (12.8)
Drugs used in addiction
disorders
135 (6.6) 134 (19.2)
Antithrombotic agents 134 (6.6) 31 (4.4)
Beta blocking agents 133 (6.5) 13 (1.9)
Antidepressants 124 (6.1) 68 (9.8)
Drugs for peptic ulcer and
gastroesophageal reflux
103 (5.1) 19 (2.7)
ACE inhibitors 101 (5.0) 21 (3.0)
Co-medications administered during the treatment period.
Anatomical Therapeutic Chemical code 3 was used
ACE angiotensin-converting enzyme, PWUD persons who
use drugs
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medication (Table 3). In PWUD, 121 (17.4%)
received 1 co-medication, 174 (25.0%) received
2–4 co-medications, 47 (6.7%) received 5–8 co-
medications, and 10 (1.4%) received more than
8 medications.
Effectiveness
In the CPSFU, the SVR12 rate was 98.0% (n/
N = 1651/1684; 95% CI 97.3–98.6) overall,
98.1% (n/N = 1432/1459; 95% CI 97.3–98.7) in
patients treated for 8 weeks, 97.0% (519/535;
95% CI 95.2–98.2) in PWUD, and 99.4% (159/
160; 95% CI 96.5–99.9) in patients with psy-
chiatric disorders (Fig. 2a). By GT, the SVR12
rate was 99.4% (890/895) for GT1, 99.4% (163/
164) for GT2, 96.2% (429/446) for GT 3, and
99.4% (153/154) for GT4–6. Thirty-three
patients did not achieve SVR12 (6 on-treatment
virologic failures; 15 relapses; 6 other virologic
failures; 2 with missing SVR12 data; and 4 dis-
continuations) (Supplementary Table 2). Of the
33 non-responders, 16 were PWUD, 1 patient
had a history of psychiatric disorder, 11 had
history of alcohol use, and 6 were PWUD and
alcohol users. Five patients treated off label also
had virologic failure (Supplementary Table 3).
SVR12 rates were similarly high ([95%) across
subgroups of interest (Fig. 2a), number of co-
medications within PWUD (Fig. 2b), and by
class of co-medication (Fig. 2c).
Health-Related Quality of Life
In the core population, the mean ± SD change
from baseline to the SVR12 visit was 2.4 ± 8.3
and 3.7 ± 10.8, for the SF-36 PCS and SF-36
MCS scores, respectively. In PWUD, the
mean ± SD change from baseline to the SVR12
visit was 2.2 ± 8.6 and 3.9 ± 11.0 for SF-36 PCS
and MCS scores, respectively. In patients with
psychiatric disorder, the mean ± SD change
from baseline to the SVR12 visit was 2.9 ± 8.2
and 5.8 ± 11.1 for SF-36 PCS and MCS scores,
respectively. The percentages of patients who
achieved improvements greater than or equal to
the MID in PROs are presented in Fig. 3a–c.
Fifty-three percent (52.6, n/N = 180/342) of
PWUD achieved improvements greater than or




Any AE 249 (12.2)
Grade C 3 20 (0.1)
DAA-related AEs 141 (6.9)
Grade C 3 5 (0.2)
Serious AEs 18 (0.9)
DAA-related serious AEsa 1 (\ 0.1)
AEs leading to discontinuation of
study drug
10 (0.5)
DAA-related AEs leading to
discontinuation of study drug
6 (0.3)
Serious AEs leading to
discontinuation of study drugb
2 (\ 0.1)
AEs leading interruption of study
drug
4 (0.2)
Fatal AEs 3 (0.1)
Deathsc,d 5 (0.2)






Post-nadir ALT[ 5 9 ULN 2/1057 (0.2)
Total bilirubin C 2 9 ULN 18/1057 (1.7)
AE adverse event, ALT alanine aminotransferase, DAA
direct-acting antiviral, ULN upper limit of normal
a Acute pericarditis, considered DAA-related by
investigator
b Septic shock and heart failure exacerbation due to res-
piratory tract infection; none were considered DAA-
related
c There were no DAA-related deaths
d Includes non-treatment-emergent deaths
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equal to the MID in SF-36 MCS from baseline at
the SVR12 visit. At the SVR12 visit, 64.0% (n/
N = 57/89) and 68.0% (n/N = 34/50) of patients
with psychiatric disorder or PWUD with psy-
chiatric disorder, respectively, achieved
improvements in SF-36 MCS scores from
baseline.
Concomitant Medicines
In the core population, more than 96.5% of
PWUD achieved SVR12 regardless of the num-
ber of concomitant medications. Patients with-
out any concomitant medications achieved an
SVR12 rate of 96.6% (253/262), and in patients
with 1, 2–4, 5–8, and more than 8 concomitant
medications SVR12 rates were 98.0% (97/99),
96.9% (125/129), 97.3% (36/37), and 100% (8/
8), respectively.
Safety
Glecaprevir/pibrentasvir had a favorable safety
profile, with one serious AE (SAE; acute peri-
carditis beginning 1 month after study drug
initiation, patient completed study drug) con-
sidered treatment-related by the investigator.
The patient with acute pericarditis had no
underlying risk factor, medical history, or fam-
ily history relevant to this SAE. The patient was
hospitalized and treated with Aspegic and col-
chicine, and was listed as making a complete
recovery. A low rate of AEs leading to premature
study drug discontinuation (n = 10; 0.5%) was
Fig. 1 Patient selection. 190 patients treated off label had
sufficient follow-up; SVR12 rate among these patients was
94.4% (85/90, 5 virologic failures). 2To date, 9 of these 13
patients have achieved SVR12 with no virologic failures.
3Patients with premature discontinuation due to AE and
last HCV RNA\ 50 IU/mL were included in the
CPSFU. AE adverse event, CPSFU core population with
sufficient follow-up, DAA direct-acting antiviral, HCV
hepatitis C virus, RNA ribonucleic acid, SVR12 sustained
virologic response at post-treatment week 12
Infect Dis Ther
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observed (Table 4). DAA-related AEs leading to
discontinuation of study drug (n = 6 overall,
0.3%) were as follows: nausea (n = 1); dizziness,
nausea, and malaise (n = 1); loss of appetite,
fatigue, and muscle cramps (n = 1); increased
creatinine value (n = 1); ascites (n = 1); head-
ache, nausea, and vomiting (n = 1). One hepatic
decompensation event (ascites) leading to dis-
continuation of study drug developed in one
patient with baseline Child–Pugh A, baseline
evidence of decreased synthetic function (hy-
poalbuminemia), and risk factors for passive
congestion of the liver (idiopathic pulmonary
fibrosis). The patient with increased creatinine
values (2.91 mg/dL at 54 days prior to first dose,
3.29 mg/dL at 28 days after first dose, 3.42 mg/
dL at 83 days after first dose, and 3.45 mg/dL at
152 days after first dose) discontinued treat-
ment 70 days after treatment initiation, had a
renal transplant in 1994, and several comor-
bidities including Alport syndrome, ischemic
heart disease, and osteoporosis. Eighteen SAEs
occurred, 17 of which were not considered
treatment-related (Supplementary Table 4); one
SAE unrelated to the study drug was observed in
the 90 patients in the off-label population with
sufficient follow-up (heart failure exacerbation
due to respiratory tract infection). The most
common AEs were asthenia (n = 43; 2.1%),
fatigue (n = 41; 2.0%), headache (n = 40; 2.0%),
and nausea (n = 20; 1.0%). Five deaths were
reported, none of which were related to treat-
ment with glecaprevir/pibrentasvir.
Elevations of alanine aminotransferase were
uncommon and did not occur with total
bilirubin elevations; no cases consistent with
drug-induced liver injury were identified. Ele-
vations of total bilirubin were rare and consis-
tent with the labeled glecaprevir/pibrentasvir-
mediated inhibition of bilirubin transport and
metabolism. Bilirubin elevations did not occur
with events of hepatic decompensation. Of the
patients with elevated alanine aminotrans-
ferase, elevations returned to baseline after
completion of treatment with glecaprevir/pi-
brentasvir in one patient and remained elevated
after treatment completion in a second patient.
DISCUSSION
Real-world studies provide valuable information
regarding treatment effectiveness and safety in
routine clinical practice, where patient popula-
tions are more heterogeneous and more inclu-
sive of marginalized populations, especially
PWUD and patients with dual disorders, than
those enrolled in clinical trials. This pooled
analysis of patient-level data from ongoing
PMOS studies demonstrates that glecaprevir/
pibrentasvir is highly effective with a favorable
safety profile across patient populations,
including in marginalized patients in routine
clinical practice from nine countries. The over-
all SVR12 rate was 98.0%, which is consistent
with that seen in the glecaprevir/pibrentasvir
registration trials (97.5%), and more recently in
the EXPEDITION-8 trial (97.7% in the inten-
tion-to-treat population) [15, 18]. This rate
remained high ([ 95%) irrespective of treat-
ment duration, cirrhosis, or subgroups of inter-
est, including patients with dual disorders.
Thirty-three patients did not achieve SVR12,
including 6 on-treatment virologic failures
(\1%), 15 relapses (1.2%), and 6 other virologic
failures (\ 1%), of which most were treatment-
naı̈ve and non-cirrhotic and 16 were PWUD.
Our results demonstrate that glecaprevir/pi-
brentasvir is an effective treatment for PWUD
with CHC across a broad range of prescribed or
non-prescribed drugs, as well as in other
underserved patient populations.
Although real-world studies of glecaprevir/
pibrentasvir use in routine clinical practice are
currently limited, our results are consistent with
bFig. 2 SVR12 rates with glecaprevir/pibrentasvir treat-
ment. a Overall and by subgroups of interest, b by number
of co-medications for PWUD within the CPSFU, c by
drug class of interest (PWUD in CPSFU). Error bars
represent 95% confidence intervals. SVR12 rate was 29/33
in patients treated with G/P for 16 weeks. 1Patients who
consumed more than two drinks/day. ARV antiretroviral,
CC compensated cirrhosis, CPSFU core population with
sufficient follow-up, G/P glecaprevir/pibrentasvir, PI pro-
tease inhibitor, OST opioid substitution treatment,
PWUD persons who use drugs, SVR12 sustained virologic
response at post-treatment week 12, TN treatment-naı̈ve,
VF virologic failure, wk week
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findings from recently published or presented
real-world studies of glecaprevir/pibrentasvir in
Germany [19, 37], Italy [20, 25], USA [23, 26],
and Scotland [24]. Similarities include the high
percentages of treatment-naı̈ve non-cirrhotic
patients ([77%), a majority of patients with
HCV GT1, and median age greater than 45 years
in this PMOS and in the other cohorts. The
small proportion of patients with CC in all
cohorts, except the 2019 German and the US
studies focusing specifically on patients with
cirrhosis, is reflective of the current disease
burden of newly diagnosed HCV-infected
patients as many patients with CC may have
been treated previously. Our study demon-
strated a high SVR12 rate among all PWUD,
capturing all drug users beyond those who
inject heroin, which is a key population for
HCV elimination. One-third (35%, n/N = 697/
2008) of the patients in our study were PWUD.
Several of the previous studies did not specifi-
cally evaluate SVR12 rate among PWUD or had
only small percentages of patients reporting
active drug use [19, 20, 23, 25, 26, 37]. It may be
that active drug use was underreported in those
studies or that active drug use remains a barrier
to DAA treatment in real-world clinical settings
across many countries.
In terms of treatment, the WHO HCV elim-
ination 2030 target is achievable because of the
availability of highly effective and well-toler-
ated pangenotypic DAAs [38]. However, only a
small number of countries are on target to
achieve this goal, often because of a lack of
diagnosis and treatment [38]. Large decreases in
HCV prevalence and incidence are possible with
increased screening and successful treatment of
CHC, particularly among groups at high risk for
transmission [39]. Within the community,
there are groups of patients that are more diffi-
cult to engage with healthcare, as they are often
underserved patients who are typically excluded
from clinical trials because of their lifestyles and
comorbidities [11]. This group includes PWUD,
patients with psychiatric disorders, unemployed
patients, those with a history of incarceration,
those with low to no education, and alcohol
users [11]. It is essential to cover these patients
with medical care in order to achieve HCV
elimination [40]. PWUD bear a high burden of
chronic HCV infection, with injection drug use
accounting for 70% of all new infections which
may be attributed to the opioid epidemic [5, 8].
In comparison to the general public, patients
with HCV have a higher burden of comorbidi-
ties and multimorbidity, including a much
higher burden of mental health and substance
and/or alcohol abuse disorders [22]. Modeling
studies have shown that treatment and suc-
cessful cure of persons who inject drugs, a
population at high risk for transmission of
HCV, may decrease prevalence and incidence
rates of HCV infections [9, 41, 42]. Historically
there have been barriers to treating these
patients including stigma, patient’s beliefs and
lack of information regarding treatment, and
perceived lack of adherence and efficacy in
these patients [6, 43, 44]. In these PMOS, gle-
caprevir/pibrentasvir treatment was well toler-
ated and highly effective with an SVR12 rate of
greater than 95% in PWUD as well as PWUD
dual disorders including PWUD in combination
with psychiatric disorders and PWUD and have
low to no education or are unemployed. Among
PWUD, the SVR12 rate was consistently high
([96%) regardless of the number of co-
medications.
Similarly, in other marginalized groups, gle-
caprevir/pibrentasvir was highly effective, as
evidenced by the high rates of SVR12 ([95%) in
patients with alcohol use, low to no education,
or who were unemployed. The SVR12 rate
(99%) was also high among patients with psy-
chiatric disorders in our study. Treatment and
management of HCV in these groups, including
implementation of harm reduction strategies
bFig. 3 Patients who achieved MID from baseline through
SVR12 visits on SF-36: a MCS, b PCS, and c FSS. Error
bars represent 95% confidence intervals. 1At least a 2.5
increase in PCS or MCS scores was considered to be a
clinically relevant improvement. 2Patients who consumed
more than two drinks/day. BL baseline, FSS fatigue
severity scale, MCS mental component summary, MID
minimally important difference, PCS physical component
summary, PTW12 post-treatment week 12, SF-36 36-Item
Short-Form Health Survey, SVR12 sustained virologic
response at post-treatment week 12, PWUD persons who
use drugs, wk week
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[45], will be critical for preventing future
infections and achieving the goal of HCV
elimination. The data from this real-world
analysis reinforces WHO, AASLD-IDSA, and
EASL guideline suggestions that these patients
should be treated [13, 14, 46], and demonstrates
that glecaprevir/pibrentasvir may be an effec-
tive and safe treatment option for PWUD and
PWUD dual disorders as well as other
marginalized patient populations in real-world
clinical practice settings. Microelimination
projects for HCV in a variety of countries may
be successful in reducing the burden of HCV,
further supporting the importance of targeting
these marginalized populations to reduce HCV
prevalence and achieve HCV elimination
[47–50]. Interestingly, there were also 192 (10%)
patients with rare genotypes (GT4–6). The
SVR12 rate was 99.4% among these patients.
This result was similar to those reported in a
previous clinical trial where glecaprevir/pi-
brentasvir achieved high SVR12 rates (97.6%) in
patients with GT4–6 [51]. The prevalence of
HCV GT4–6 is increasing in North America and
Europe as a result of migration from the Middle
East, Africa, and Southeast Asia [52]. With the
successful development of pangenotypic DAAs,
there is a unique opportunity to achieve global
HCV elimination among patients with rare
genotypes as well as other marginalized
populations.
Most patients in this study and other repor-
ted registries were non-cirrhotic and treatment-
naive and received glecaprevir/pibrentasvir for
8 weeks. In this analysis, 408 patients in the
PWUD population were treatment-naı̈ve and
received treatment for 8 weeks. The SVR12 was
high ([95%) among patients treated for
8 weeks. Thirteen treatment-naı̈ve patients with
CC received 8-week glecaprevir/pibrentasvir, of
which nine achieved SVR12 with no virologic
failures (SVR12 for the remaining patients are
pending). Previous real-world data have also
demonstrated high SVR12 rates among patients
receiving 8-week glecaprevir/pibrentasvir
[19, 23–26, 37, 43]. These data suggest that
glecaprevir/pibrentasvir may be an appropriate
and effective treatment option for all patients
with CHC, including PWUD and other under-
served populations. Indeed, glecaprevir/
pibrentasvir is now available in a shorter,
8-week once-daily option for treatment-naı̈ve
patients with CC and HCV GT1–6 [15]. This is
supported by data from the EXPEDITION-8
study with an SVR12 rate of 97.7% in GT1–6,
and one virologic failure [18]. There are many
potential benefits to shorter duration treat-
ments for HCV, including the ability to reach
patients in a broader range of community set-
tings, improve adherence rates [53], and reduce
medical costs. In particular, the healthcare
resources saved with a shortened treatment
duration, in terms of reduced number of visits
with specialists, costs, and related complica-
tions (extrahepatic and hepatic), have the
potential to increase the number of patients
treated within specific healthcare budgets [54].
Increasing the number of patients who are
treated for HCV may reduce the time until HCV
elimination is achieved [54]. There are other
settings not included in this study in which
8-week treatment may prove to be beneficial
including in prisons, particularly where patients
are transferred or released during treatment,
and in refugee camps where the prevalence of
HCV is reported to be relatively high and
patient engagement difficult [55, 56].
In addition to the high rates of SVR,
improvements in HRQOL were also observed in
patients with CHC treated with glecaprevir/pi-
brentasvir from baseline to the SVR12 visit, with
the proportion of patients meeting the MID
threshold higher at SVR12 than EOT. The mean
change from baseline to the SVR12 visit in SF-36
MCS was clinically meaningful. Greater than
45% of patients experienced a clinically mean-
ingful improvement in the mental components
of HRQOL; this was most evident in patients
with psychiatric disorders, PWUD combined
with psychiatric disorders, and PWUD com-
bined with alcohol users. Previously, treatment
of HCV with DAAs was demonstrated to
improve PROs, including HRQOL, particularly
among PWUD and patients on opioid substitu-
tion therapy [32]. A similar percentage (40.8%)
of patients experienced a clinically meaningful
decrease in fatigue. The impact of fatigue on
patients with CHC was previously documented
in clinical trials [27]. These results suggest that,
in the short term, successful treatment with
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glecaprevir/pibrentasvir alleviates some symp-
toms associated with CHC infection. This evi-
dence may support the treatment of patients
with extrahepatic manifestations for whom
HRQOL is reduced [57].
Although AEs may be underreported in real-
world clinical settings, glecaprevir/pi-
brentasvir’s safety profile in this study is con-
sistent with that observed in the registration
trials [15, 19, 20]. Overall, glecaprevir/pi-
brentasvir had a favorable safety profile: there
was a low rate of SAEs reported with only one
SAE (\0.1%) considered treatment-related
observed as well as a low rate of study drug
discontinuation as a result of AEs. Observed
laboratory abnormalities and hepatic decom-
pensation events were also rare. Bilirubin ele-
vations were consistent with that described in
the label from the glecaprevir/pibrentasvir
inhibition of bilirubin transport and metabo-
lism. No cases consistent with drug-induced
liver injury were identified and the single
reported case of hepatic decompensation
(ascites) in a patient with CC may be
attributable to the natural course of the
patient’s underlying liver disease.
Limitations
Similar to other real-world observational stud-
ies, bias may exist in the reporting and collec-
tion of patient-level information. Adverse
events, non-adherence, and recreational drug
use are often underreported in real-world set-
tings. Recreational drug use and adherence to
treatment were patient-reported. This study had
a high level of patients who were lost to follow-
up, which may impact the rates of SVR12
observed and may be of concern in populations
with ongoing risk who have potential for
reinfection.
CONCLUSION
Our results demonstrate that glecaprevir/pi-
brentasvir is a well-tolerated and highly effec-
tive pangenotypic treatment option for a broad
range of marginalized patients with CHC and
single or dual disorders. These real-world results
complement those seen in the glecaprevir/pi-
brentasvir registrational program and close
current gaps in clinical knowledge regarding
impact on HRQOL. Our results further support
the use of 8-week short-course pangenotypic
glecaprevir/pibrentasvir in underserved patients
including those with substance abuse and psy-
chiatric comorbidities, addressing barriers to
HCV elimination including widespread stigma
and lack of confidence in treating underserved
patient groups and may provide the impetus to
meet the WHO elimination targets.
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et al. Difficulties in initiating hepatitis C treatment
in patients with opioid usdisorder: patient’s per-
spective. Heroin Addict Relat Clin Probl. 2019;21:
47–51.
45. Fraser H, Martin NK, Brummer-Korvenkontio H,
et al. Model projections on the impact of HCV
treatment in the prevention of HCV transmission
among people who inject drugs in Europe. J Hepa-
tol. 2018;68(3):402–11.




68BE7F9B?sequence=1. Accessed 10 Feb 2021.
47. Benzaken AS, Girade R, Catapan E, et al. Hepatitis C
disease burden and strategies for elimination by
2030 in Brazil. A mathematical modeling approach.
Braz J Infect Dis. 2019;23(3):182–90.
48. Calleja Panero JL, Lens Garcia S, Fernandez Bermejo
M, Crespo J. Definition of the profiles of hepatitis C
virus patients based on the identification of risky
practices in Spain. Rev Esp Enferm Dig.
2019;111(10):731–7.
49. Chen Q, Ayer T, Bethea E, et al. Changes in hep-
atitis C burden and treatment trends in Europe
during the era of direct-acting antivirals: a mod-
elling study. BMJ Open. 2019;9(6):e026726.
50. Wade AJ, Doyle JS, Gane E, et al. Outcomes of
treatment for hepatitis C in primary care, compared
to hospital-based care: a randomized, controlled
trial in people who inject drugs. Clin Infect Dis.
2020;70(9):1900–6.
51. Asselah T, Lee SS, Yao BB, et al. Efficacy and safety
of glecaprevir/pibrentasvir in patients with chronic
hepatitis C virus genotype 5 or 6 infection
(ENDURANCE-5,6): an open-label, multicentre,
phase 3b trial. Lancet Gastroenterol Hepatol.
2019;4(1):45–51.
52. Asselah T, Hassanein T, Waked I, Mansouri A,
Dusheiko G, Gane E. Eliminating hepatitis C within
low-income countries—the need to cure genotypes
4, 5, 6. J Hepatol. 2018;68(4):814–26.
53. Akiyama MJ, Norton BL, Arnsten JH, Agyemang L,
Heo M, Litwin AH. Intensive models of hepatitis C
care for people who inject drugs receiving opioid
agonist therapy: a randomized controlled trial. Ann
Intern Med. 2019;170(9):594–603.
54. Feld JJ, Sanchez Gonzalez Y, Pires AG, Ethgen O.
Clinical benefits, economic savings and faster time
to HCV elimination with a simplified 8-week
treatment and monitoring program in chronic
F0–F3 naı̈ve patients in the US. Hepatology.
2018;68(suppl 1):2 (abstract 688).
55. Aspinall EJ, Mitchell W, Schofield J, et al. A mat-
ched comparison study of hepatitis C treatment
outcomes in the prison and community setting,
and an analysis of the impact of prison release or
transfer during therapy. J Viral Hepat. 2016;23(12):
1009–16.
56. Galli M, Ridolfo A, van denBogaart L, Negri C,
Giacomelli A. HCV and immigration in Italy. Acta
Biomed. 2018;89(Suppl 10):19–32.
57. Negro F, Forton D, Craxı̀ A, Sulkowski MS, Feld JJ,
Manns MP. Extrahepatic morbidity and mortality
of chronic hepatitis C. Gastroenterology.
2015;149(6):1345–60.
Infect Dis Ther
